Risk Reduction in Coronary Heart Disease - a Prospective Randomized Study
Multifactorial risk reduction in coronary heart disease reduces the risk of new coronary heart disease and death
Status: Recruiting (N/A). Started on September 1st, 2007.
Enrollment: 1600 subjects
Study Type: Interventional
Study Design:
- Allocation: Randomized
- Endpoint Classification: Efficacy Study
- Intervention Model: Parallel Assignment
- Masking: Open Label
- Primary Purpose: Prevention
Conditions:
Interventions:
- Behavioral: smoking cessation
- Drug: betablocker, diuretics, ACEI, ARB,
- Drug: statins (simvastatin, atorvastatin), ezetimib
- Behavioral: training
- Biological: influenza vaccine
- Drug: metformin, glimepiride, insulin
- Behavioral: weight reduction
Eligibility
Inclusion Criteria:
- acute myocardial infarction, CABG or PCI
Exclusion Criteria:
Age < 18 and age > 80
pregnant
critical illness
drug abuse
- Gender
Both
- Mininum Age
18 Years
- Maximum Age
79 Years
- Healthy Volunteers
No
Resources
Source: Sorlandet Hospital HF
Authority: Norway: Norwegian Social Science Data Services
Locations
-
Sorlandet Hospital
Arendal
Norway
Officials
Serena Tonstad, dr.med. (Study Chair, Ullevaal University Hospital)
Sponsors
Sorlandet Hospital HF (Lead Sponsor)
Ullevaal University Hospital (Collaborator)
References
None.
Links
None.
- Date Verified
- December 1st, 2011
- First Received
- December 21st, 2011
- Last Changed
- December 21st, 2011
Information obtained from ClinicalTrials.gov on December 21, 2011. Link to the current ClinicalTrials.gov record.
All data in the Healia Clinical Trials Information Database and content displayed by the Healia Clinical Trials Search Engine are licensed from the National Institutes of Health (National Library of Medicine), which collects and maintains the data.
The Healia Clinical Trials Search Engine searches the data set at clinicaltrials.gov, providing up-to-date information about current clinical trials. In the Healia Clinical Trials Database you can find information on new experimental drugs, medical devices, and other types of treatments for all types of diseases. Each clinical trial description includes information about the phase of the trial (phase I, phase II, or phase III), the trial’s methods, such as whether it is a randomized, placebo controlled, double blind study, and the status of the trial including whether or not the trial is currently enrolling new participants.